Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality (PALERMO)
Phase III Study, Randomized, Multicenter, Evaluating the Efficacy of a Cardiovascular Active Prevention Vs Usual Clinical Practice, on the Morbi-mortality Decrease in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitor
Sponsor: University Hospital, Angers
Terminated
Inclusions stopped on 25MAR2022 due to lack of inclusion Last follow-up on 16APR2024
Other terminated trials from University Hospital, Angers
Other Chronic Myeloid Leukemia (CML) trials with similar outcome
Listed as NCT03746054, this PHASE3 trial focuses on Chronic Myeloid Leukemia (CML) and remains terminated or withdrawn. Sponsored by University Hospital, Angers, it has been updated 11 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE3
Status: Unknown → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Unknown PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Active Not Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Mar 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE3
-
Dec 2018 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Hospital, Angers
For direct contact, visit the study record on ClinicalTrials.gov .